CALT — Calliditas Therapeutics AB Share News
0.000.00%
Last trade - 00:00- $1.10bn
- $1.12bn
- SEK1.21bn
Brief: Calliditas Therapeutics Announces Full FDA Approval Of TARPEYO
What to Watch in the Week Ahead and on Monday, December 18
Brief: Calliditas Receives Notice Of Allowance In U.S For Tarpeyo
Brief: Calliditas' Partner Everest Medicines Announces China NMPA's Approval
Brief: Calliditas Therapeutics Reconfirms Net Sales Guidance For 2023
Brief: Calliditas Q3 Sales at SEK 294.6 Million
Guggenheim says Calliditas' kidney disease drug likely to get full US approval; shares rise
Novartis drug candidate scores interim win in rare kidney disease trial (updated)
Brief: Calliditas Says Nefecon Application Approval In Macau
Calliditas rises on positive EMA feedback for genetic disease drug
Brief: Calliditas Therapeutics - EMA Gives Positive Opinion On Application For Setanaxib
Brief: Calliditas Announces Filing With UK MHRA For Kinpeygo In IgA Nephropathy
Brief: Calliditas Files For Full Marketing Authorization Of Kinpeygo® In EU
Brief: Calliditas Therapeutics Granted Orphan Drug Designation By FDA For Treatment Of Alport Syndrome With Setanaxib
Brief: Calliditas Therapeutics Granted Orphan Drug Designation By FDA For Treatment Of Alport Syndrome With Setanaxib
Brief: Everest Medicines Says Partner Calliditas Therapeutics Receives FDA Priority Review For Full Approval Of Nefecon
Brief: Calliditas Receives FDA Priority Review For Approval Of Tarpeyo
Calliditas Therapeutics rises as FDA grants priority review to kidney disease drug
Brief: Calliditas Q2 Net Sales SEK 269.4 Million